Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Eisen T, et al. Among authors: xia c. Br J Cancer. 2006 Sep 4;95(5):581-6. doi: 10.1038/sj.bjc.6603291. Epub 2006 Aug 1. Br J Cancer. 2006. PMID: 16880785 Free PMC article. Clinical Trial.
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ. Ratain MJ, et al. Among authors: xia c. J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636341 Clinical Trial.
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. Flaherty KT, et al. Among authors: xia c. Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. Clin Cancer Res. 2008. PMID: 18676756 Clinical Trial.
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM; ARCCS Study Investigators. Stadler WM, et al. Among authors: xia c. Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864. Cancer. 2010. PMID: 20082451 Free article.
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. McDermott DF, et al. Among authors: xia c. J Clin Oncol. 2008 May 1;26(13):2178-85. doi: 10.1200/JCO.2007.14.8288. J Clin Oncol. 2008. PMID: 18445842 Clinical Trial.
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA. Bukowski RM, et al. Among authors: xia c. Oncology. 2010;78(5-6):340-7. doi: 10.1159/000320223. Epub 2010 Aug 20. Oncology. 2010. PMID: 20733337
4,281 results